- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07832981
Wellness Program Participation and Changes in Health and Quality of Life in Adults and Children
Association Between Participation in a Comprehensive Wellness Program and Changes in Functional, Nutritional, and Quality of Life Outcomes Among Adults and Children - an Observational Study
The goal of this observational study is to learn how health and quality of life change over time in adults and children aged 2 years and older. It will also examine how these changes are related to participation in wellness activities and the use of nutritional supplements.
The main questions this study aims to answer are:
How do measures of health, physical function, and quality of life change over time? Are changes in these measures associated with participation in a wellness program, nutritional supplement use, or other health and lifestyle factors?
Participants may:
Answer questions about their health, lifestyle, physical activity, sleep, fatigue, stress, and quality of life.
Complete physical and functional assessments. Choose to provide blood samples for laboratory testing. Complete follow-up assessments over time.
This is an observational study. Researchers will not assign participants to a wellness program or any other intervention or tell participants which supplements to use. Any wellness program participation or supplement use occurs independently of the study.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Kaitlyn Hofmeister
- Phone Number: 951-228-4222
- Email: k.hofmeister@drgoodenowe.com
Study Locations
-
-
Saskatchewan
-
Moose Jaw, Saskatchewan, Canada, S6H 7T2
- Lakeview Regional Wellness Centre
-
Principal Investigator:
- Dayan Goodenowe, PhD
-
-
-
-
California
-
Temecula, California, United States, 92590
- Restorative Health Center
-
Principal Investigator:
- Dayan Goodenowe, PhD
-
Sub-Investigator:
- Stan Mokoko Sr, MD, MS-CRA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Individuals aged 2 years and older, with or without chronic health conditions, may participate. The study population may include individuals who independently participate in a comprehensive wellness program and individuals who do not participate in a wellness program but consent to research-only assessments. Participants will be recruited through program enrollment communications, community outreach, social media, and referrals from health care providers.
Description
Inclusion Criteria:
- Age 2 years or older
- Able to provide informed consent, or parent or legally authorized representative able to provide informed consent
- Able to provide assent, if age 7 years or older
- Willing and able to complete baseline and follow-up assessments according to the study schedule
- Willing to allow use of wellness program data for research, if enrolling in a wellness program
Exclusion Criteria:
- Participant or caregiver unable to provide informed consent
- Expected inability to complete follow-up
- Concurrent enrollment in an interventional clinical trial that would substantially confound outcomes of interest
- Any condition that, in the opinion of the investigator, would make participation unsafe or unreliable
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in N100 amplitude measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in N100 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform. N100 amplitude represents the magnitude of the electrophysiological response associated with early auditory sensory processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change from baseline in N100 latency measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in N100 ERP latency, measured in milliseconds (ms) using the NeuroCatch portable EEG platform. N100 latency represents the timing of the electrophysiological response associated with early auditory sensory processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change from baseline in P300 amplitude measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in P300 ERP amplitude, measured in microvolts (µV) using the NeuroCatch portable EEG platform. P300 amplitude represents the magnitude of the electrophysiological response associated with attentional and orienting processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change from baseline in P300 latency measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in P300 ERP latency, measured in milliseconds (ms) using the NeuroCatch portable EEG platform. P300 latency represents the timing of the electrophysiological response associated with attentional processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change from baseline in N400 amplitude measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in N400 ERP amplitude, measured in microvolts (µV) using the NeuroCatch portable EEG platform. N400 amplitude represents the magnitude of the electrophysiological response associated with higher-order semantic processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change from baseline in N400 latency measured using the NeuroCatch Platform
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in N400 ERP latency, measured in milliseconds (ms) using the NeuroCatch portable EEG platform. N400 latency represents the timing of the electrophysiological response associated with higher-order semantic processing. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Heart Rate Recovery Assessed by Electrocardiography
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in heart rate recovery following a standardized physiological challenge will be assessed using electrocardiography (ECG). Heart rate recovery will be calculated as the difference between the heart rate at the end of the challenge and the heart rate measured at a prespecified recovery time point (1 minute) after cessation of the challenge. Heart rate recovery will be reported in beats per minute (bpm). A larger decrease in heart rate during the recovery period indicates faster cardiac autonomic recovery. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Body Composition as Measured by the InBody Bioelectrical Impedance Analysis (BIA) System
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in body composition will be assessed using an InBody bioelectrical impedance analysis (BIA) device. Body composition parameters will include percent body fat (%), body fat mass (kg), and skeletal muscle mass (kg). Changes in each parameter will be calculated as the value at the follow-up assessment minus the corresponding baseline value, expressed as a percentage. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Forced Expiratory Volume in One Second to Forced Vital Capacity (FEV1/FVC) Ratio as Measured by Spirometry
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the ratio of Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FEV1/FVC) will be assessed using spirometry. The FEV1/FVC ratio represents the proportion of the total forced vital capacity that is exhaled during the first second of a forced expiratory maneuver and will be expressed as a percentage. Change will be calculated as the follow-up FEV1/FVC value minus the corresponding baseline value and will be expressed as a percentage in relation to the baseline. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Hand Grip Strength as Measured by a Handgrip Dynamometer
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in hand grip strength will be assessed using a handgrip dynamometer and reported in kilograms (kg). Hand grip strength represents the maximal voluntary isometric force generated during a handgrip contraction. Grip strength will be measured in both the right and left hands. The highest valid grip-strength measurement from three attempts for each hand will be identified. Overall hand grip strength will be calculated as the average of the best right-hand and best left-hand measurements. This averaged value, expressed in kg, will constitute the reported hand grip strength for each assessment. Change from baseline will be calculated as the follow-up overall hand grip strength value minus the baseline overall hand grip strength value and will be expressed as a percentage in relation to the baseline. A positive change indicates increased grip strength, while a negative change indicates decreased grip strength. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Timed Up and Go (TUG)
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in functional mobility as assessed using the Timed Up and Go test. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Dynamic Gait Index
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in gait and balance as assessed using the Dynamic Gait Index. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Symbol Digit Modalities Test
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in cognitive performance as assessed using the Symbol Digit Modalities Test. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Distance Visual Acuity as Measured Using a Snellen Visual Acuity Chart
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in distance visual acuity will be assessed using a Snellen visual acuity chart. Visual acuity represents the ability to distinguish letters or symbols at a standardized testing distance and will be recorded as a Snellen fraction (e.g., 20/20). Visual acuity will be assessed according to the study's standardized vision assessment protocol. Change from baseline will be determined by comparing the follow-up visual acuity measurement with the corresponding baseline measurement. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Total Physical Activity as Assessed by the International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in total physical activity will be assessed using the International Physical Activity Questionnaire - Short Form (IPAQ-SF). The questionnaire assesses self-reported physical activity performed during the previous 7 days, including walking, moderate-intensity activity, and vigorous-intensity activity. Physical activity will be summarized as total Metabolic Equivalent of Task minutes per week (MET-minutes/week) according to the standardized IPAQ scoring protocol. Total physical activity is calculated from the reported frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity, weighted by their corresponding MET values. Higher MET-minutes/week indicate a greater level of physical activity and are generally considered a more favorable outcome in the context of this wellness study. Change from baseline will be calculated as the follow-up total physical activity score in MET-minutes/week minus the corresponding baseline score. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Simple Lifestyle Indicator Questionnaire (SLIQ) Score
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Simple Lifestyle Indicator Questionnaire (SLIQ) overall score. The SLIQ is a 12-item questionnaire that assesses five lifestyle domains: diet, physical activity, alcohol consumption, smoking, and stress. The overall SLIQ score ranges from 0 to 10, with higher scores indicating a healthier lifestyle. A positive change from baseline indicates improvement in overall lifestyle. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Fatigue Severity Scale (FSS) Score
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Fatigue Severity Scale (FSS) score. The FSS is a 9-item self-reported questionnaire that assesses the severity of fatigue and its impact on daily functioning. Each item is rated on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree). The overall FSS score is calculated as the mean of the nine item scores and ranges from 1 to 7. Higher scores indicate greater fatigue severity and therefore a worse outcome. A negative change from baseline indicates an improvement in fatigue severity. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in 10-Item Perceived Stress Scale (PSS-10) Score
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the 10-Item Perceived Stress Scale (PSS-10) score. The PSS-10 is a 10-item self-reported questionnaire that assesses the degree to which situations in an individual's life are perceived as stressful. Each item is rated on a 5-point scale from 0 (never) to 4 (very often), with positively worded items reverse scored. Item scores are summed to produce a total score ranging from 0 to 40. Higher scores indicate greater perceived stress and therefore a worse outcome. A negative change from baseline indicates an improvement (reduction) in perceived stress. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Participant-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 (PROMIS-10) Scores
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Participant-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 (PROMIS-10) scores. The PROMIS-10 is a 10-item patient-reported questionnaire assessing global physical, mental, and social health. The measure provides separate Global Physical Health and Global Mental Health summary scores. For each summary domain, the raw summed score ranges from 4 to 20 and is converted to a standardized T-score. Global Physical Health T-scores range from 16.2 to 67.7, and Global Mental Health T-scores range from 21.2 to 67.6. Higher T-scores indicate better physical or mental health and therefore a better outcome. A positive change from baseline indicates improvement in global health. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) Domain Scores
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) domain scores. The WHOQOL-BREF is a 26-item self-reported questionnaire that assesses quality of life across four domains: Physical Health, Psychological Health, Social Relationships, and Environment. Domain scores are transformed to a 0 to 100 scale, with higher scores indicating better quality of life and therefore a better outcome. A positive change from baseline indicates an improvement in quality of life. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Cognitive Function Score (Short form)
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. The Neuro-QoL Cognitive Function measure is a patient-reported assessment of perceived cognitive abilities, including areas such as memory, attention, concentration, and executive functioning. Responses are converted to standardized T-scores, with a reference population mean of 50 and a standard deviation of 10. The minimum and maximum attainable T-scores for short form Neuro-QoL Cognitive Function are 17.3 and 64.2. Higher T-scores indicate better perceived cognitive function and therefore a better outcome. A positive change from baseline indicates improvement in cognitive function. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Pittsburgh Sleep Quality Index (PSQI) global score. The PSQI is a 19-item self-reported questionnaire that assesses sleep quality and sleep disturbances over the past month across seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and the seven component scores are summed to produce a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality and therefore a worse outcome. A negative change from baseline indicates improvement in overall sleep quality. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Serum Phospholipid, Fatty Acid, and Gastrointestinal Tract Acid Levels
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in serum lipid biomarkers measured by mass spectrometry, including ethanolamine phospholipids, DHA ethanolamine phospholipids, choline phospholipids, DHA choline phospholipids, dietary fatty acids (omega-3, omega-6, omega-9, oleic acid [OA], linoleic acid [LA], and arachidonic acid [AA]), and gastrointestinal tract acids (GTAs). Changes will be expressed as fold-change relative to baseline. For each biomarker, fold-change is calculated as the serum level at the specified follow-up time point divided by the corresponding baseline level. A fold-change of 1.0 indicates no change from baseline, a value greater than 1.0 indicates an increase from baseline, and a value less than 1.0 indicates a decrease from baseline. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Change From Baseline in Serum Clinical Chemistry Biomarkers
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in serum clinical chemistry biomarkers measured using the Architect system, including glucose, calcium, blood urea nitrogen (BUN), creatinine, albumin, total protein, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), homocysteine, C-reactive protein (CRP), total iron, triacylglycerols, cholesterol, high-density lipoprotein (HDL), and uric acid. Changes will be expressed as fold-change relative to baseline. For each biomarker, fold-change is calculated as the serum level at the specified follow-up time point divided by the corresponding baseline level. A fold-change of 1.0 indicates no change from baseline, a value greater than 1.0 indicates an increase from baseline, and a value less than 1.0 indicates a decrease from baseline. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11) Score
Time Frame: Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
Change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. The ADAS-Cog-11 is a clinician-administered assessment of cognitive performance that evaluates domains including memory, language, orientation, and praxis. Individual item scores are summed to produce a total score ranging from 0 to 70. Higher scores indicate greater cognitive impairment and therefore a worse outcome. A negative change from baseline indicates improvement in cognitive performance. |
Baseline; monthly through Month 6; Months 9, 12, 18, and 24; and annually thereafter through 5 years.
|
|
Participant Characteristics Associated With Adherence and Engagement
Time Frame: Baseline; Months 3, 6, and 12; annually thereafter
|
Association between participant characteristics and study adherence will be explored over the study period. Study adherence will be assessed as the percentage of planned study activities completed by each participant, calculated as the number of completed planned study activities divided by the total number of planned study activities, multiplied by 100. The reported unit of measure will be percentage (%), ranging from 0% to 100%, with higher percentages indicating greater study adherence. Participant characteristics will be evaluated as explanatory variables in exploratory statistical analyses and will not be combined with adherence into a composite outcome. |
Baseline; Months 3, 6, and 12; annually thereafter
|
|
Association Between Change from Baseline in N100 ERP Amplitude and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N100 ERP Latency and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Amplitude and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Latency and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Amplitude and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Latency and ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N100 ERP Amplitude and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N100 ERP Latency and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Amplitude and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Latency and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Amplitude and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Latency and Neuro-QoL Cognitive Function Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Cognitive Function score. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N100 ERP Amplitude and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N100 ERP Latency and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N100 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Amplitude and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in P300 ERP Latency and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in P300 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Amplitude and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) amplitude, measured in microvolts (µV) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in N400 ERP Latency and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between change from baseline in N400 event-related potential (ERP) latency, measured in milliseconds (ms) using the NeuroCatch portable electroencephalography (EEG) platform and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to the baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Self-Reported Supplement Categories and Change From Baseline in Serum Lipid Biomarkers
Time Frame: Baseline and months 3, 6, 12, 24, 36, 48, and 60
|
To evaluate the association between self-reported supplement categories at each study visit and change from baseline in serum lipid biomarkers at the corresponding study visit, measured by mass spectrometry and expressed as fold change relative to baseline. |
Baseline and months 3, 6, 12, 24, 36, 48, and 60
|
|
Association Between Program Participation and Change from Baseline in Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between self-reported program participation (yes/no) at each study visit and change from baseline in serum lipid biomarkers at the corresponding study visit, measured by mass spectrometry and expressed as fold change relative to baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Supplement Categories and Change from Baseline in ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between self-reported supplement categories at each study visit and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score at the corresponding study visit. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Program Participation and Change from Baseline in ADAS-Cog-11 Total Score
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
To evaluate the association between self-reported program participation (yes/no) at each study visit and change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score at the corresponding study visit. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in ADAS-Cog-11 Total Score and Serum Lipid Biomarkers
Time Frame: Baseline and months 3, 6, 12, 24, 36, 48, and 60.
|
The association between change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11) total score and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to baseline. |
Baseline and months 3, 6, 12, 24, 36, 48, and 60.
|
|
Association Between Change from Baseline in WHOQOL-BREF Domain Scores and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
The association between change from baseline in World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) domain score and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
|
Association Between Change from Baseline in FEV₁/FVC Ratio and Serum Lipid Biomarkers
Time Frame: Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
The association between change from baseline in FEV₁/FVC ratio and change from baseline in serum lipid biomarkers measured by mass spectrometry and expressed as fold change relative to baseline. |
Baseline and 3, 6, 12, 24, 36, 48, and 60 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dayan Goodenowe, PhD, Dr. Goodenowe Research LLC
Publications and helpful links
General Publications
- Jess T, Jensen BW, Andersson M, Villumsen M, Allin KH. Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2020 Apr;18(4):881-888.e1. doi: 10.1016/j.cgh.2019.07.052. Epub 2019 Aug 5.
- Tardy AL, Pouteau E, Marquez D, Yilmaz C, Scholey A. Vitamins and Minerals for Energy, Fatigue and Cognition: A Narrative Review of the Biochemical and Clinical Evidence. Nutrients. 2020 Jan 16;12(1):228. doi: 10.3390/nu12010228.
- Prokes L, Gorylova M, Cermak Sraitrova K, Nazabal V, Havel J, Nemec P. Arsenic-Doped SnSe Thin Films Prepared by Pulsed Laser Deposition. ACS Omega. 2021 Jun 30;6(27):17483-17491. doi: 10.1021/acsomega.1c01892. eCollection 2021 Jul 13.
- Zhang H, Qi G, Wang K, Yang J, Shen Y, Yang X, Chen X, Yao X, Gu X, Qi L, Zhou C, Sun H. Oxidative stress: Roles in skeletal muscle atrophy. Biochem Pharmacol. 2023 Aug;214:115664. doi: 10.1016/j.bcp.2023.115664. Epub 2023 Jun 16.
- Hurtado-Torres GF. Comment on: Chocolate Consumption and Risk of Coronary Heart Disease, Stroke, and Diabetes: A Meta-analysis of prospective Studies, Nutrients 2017, 9, 688. Nutrients. 2017 Aug 9;9(8):852. doi: 10.3390/nu9080852.
- Day AH , Domarkas J , Nigam S , Renard I , Cawthorne C , Burke BP , Bahra GS , Oyston PCF , Fallis IA , Archibald SJ , Pope SJA . Towards dual SPECT/optical bioimaging with a mitochondrial targeting, 99mTc(i) radiolabelled 1,8-naphthalimide conjugate. Dalton Trans. 2020 Jan 2;49(2):511-523. doi: 10.1039/c9dt04024b.
- Sahm F, Kalamarides M. TERT, the target? Neuro Oncol. 2018 Nov 12;20(12):1561-1562. doi: 10.1093/neuonc/noy138. No abstract available.
- Yamaguchi-Shinozaki K, Shinozaki K. Transcriptional regulatory networks in cellular responses and tolerance to dehydration and cold stresses. Annu Rev Plant Biol. 2006;57:781-803. doi: 10.1146/annurev.arplant.57.032905.105444.
- Tanaka K, Iwata T, Yoshida S, Nishii K, Matsui Y, Sugiyama T, Itami M, Iizasa T. A surgical case of synchronous solitary splenic metastasis from lung squamous cell carcinoma: report of a case and review of the literature. Gen Thorac Cardiovasc Surg. 2020 Aug;68(8):866-870. doi: 10.1007/s11748-019-01275-4. Epub 2019 Dec 16.
- Solberg B. From Prenatal Diagnosis to Preterm Infants: A Cultural Guide to Understand Scandinavian Variation. Pediatrics. 2018 Sep;142(Suppl 1):S593-S599. doi: 10.1542/peds.2018-0478L.
- Brouwers MC. Electrolyte and Acid-Base Disturbances in Diabetes Mellitus. N Engl J Med. 2015 Dec 17;373(25):2482. doi: 10.1056/NEJMc1511638. No abstract available.
- Yakimovich KM, Orland C, Emilson EJS, Tanentzap AJ, Basiliko N, Mykytczuk NCS. Lake characteristics influence how methanogens in littoral sediments respond to terrestrial litter inputs. ISME J. 2020 Aug;14(8):2153-2163. doi: 10.1038/s41396-020-0680-9. Epub 2020 May 18.
- Mishra S, Maiti S, Dwadasi BS, Rai B. Realistic microstructure evolution of complex Ta-Nb-Hf-Zr high-entropy alloys by simulation techniques. Sci Rep. 2019 Nov 8;9(1):16337. doi: 10.1038/s41598-019-52170-0.
- Jodar E, Artola S, Garcia-Moll X, Uria E, Lopez-Martinez N, Palomino R, Martin V. Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001130. doi: 10.1136/bmjdrc-2019-001130.
- Smith AD, Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Annu Rev Nutr. 2016 Jul 17;36:211-39. doi: 10.1146/annurev-nutr-071715-050947.
- Chew EY, Clemons TE, Agron E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640.
- Papadopoulou SK, Papadimitriou K, Voulgaridou G, Georgaki E, Tsotidou E, Zantidou O, Papandreou D. Exercise and Nutrition Impact on Osteoporosis and Sarcopenia-The Incidence of Osteosarcopenia: A Narrative Review. Nutrients. 2021 Dec 16;13(12):4499. doi: 10.3390/nu13124499.
- Papadopoulou SK. Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients. 2020 May 1;12(5):1293. doi: 10.3390/nu12051293.
- Candow DG, Forbes SC, Ostojic SM, Prokopidis K, Stock MS, Harmon KK, Faulkner P. "Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and Function. Sports Med. 2023 Dec;53(Suppl 1):49-65. doi: 10.1007/s40279-023-01870-9. Epub 2023 Jun 27.
- Maisel P, Baum E, Donner-Banzhoff N. Fatigue as the Chief Complaint-Epidemiology, Causes, Diagnosis, and Treatment. Dtsch Arztebl Int. 2021 Aug 23;118(33-34):566-576. doi: 10.3238/arztebl.m2021.0192.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DGR-202604
- Pro00094920 (Other Identifier: Advarra IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.